Literature DB >> 9267327

Prostate-specific antigen expression in a case of intracystic carcinoma of the breast: characterization of immunoreactive protein and literature surveys.

F Mannello1, M Sebastiani, S Amati, G Gazzanelli.   

Abstract

A case is presented of female breast intracystic carcinoma with prostate-specific antigen (PSA) expressed in high amounts in aspirated cystic fluid (55 micrograms/L). Tumor extract analysis revealed the presence of both estrogen and progesterone receptors (0.38 and 1.87 nmol/L, respectively) and high quantities of PSA too (19.52 micrograms/L). Chromatographic analysis of cystic fluid revealed two peaks of PSA, at the expected positions for free and bound serine protease. A major proportion of 33-kDa free from was also confirmed by Western blotting analysis. Free PSA was heat-stable at 56 degrees C and displayed no change after freezing-thawing. These findings are discussed in the context of a detailed literature survey. Our data support the contention that PSA immunoreactivity in intracystic fluid of breast carcinoma is partly the result of secretory activity by the neoplastic cells and that the steroid receptors can also modulate its expression.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9267327

Source DB:  PubMed          Journal:  Clin Chem        ISSN: 0009-9147            Impact factor:   8.327


  3 in total

1.  Differential distribution of soluble and complexed forms of prostate-specific antigen in cyst fluids of women with gross cystic breast disease.

Authors:  M Malatesta; F Mannello; M Sebastiani; G Gazzanelli
Journal:  J Clin Lab Anal       Date:  2001       Impact factor: 2.352

Review 2.  Reconnoitring the status of prostate specific antigen and its role in women.

Authors:  Prakruti Dash
Journal:  Indian J Clin Biochem       Date:  2014-06-22

Review 3.  Prostate-specific antigen (PSA/hK3): a further player in the field of breast cancer diagnostics?

Authors:  F Mannello; G Gazzanelli
Journal:  Breast Cancer Res       Date:  2001-05-10       Impact factor: 6.466

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.